NCT00490620View on ClinicalTrials.gov

Study of Combivir for Patients With Primary Biliary Cirrhosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

April 30, 2007

Conditions
Primary Biliary Cirrhosis
Interventions
DRUG

Combination antiviral therapy

Zidovudine 300mg and lamivudine 150mg BID for 6 months

DRUG

Placebo

placebo BID for 6 months

Trial Locations (5)

55905

Mayo Clinic, Rochester

63103

St Louis University, St Louis

T5N 1Y9

University of Alberta, Edmonton

H3C 3J7

University of Montreal, Montreal

B15 2TH

University of Birmingham, Birmingham

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Axcan Pharma

INDUSTRY

lead

University of Alberta

OTHER

NCT00490620 - Study of Combivir for Patients With Primary Biliary Cirrhosis | Biotech Hunter | Biotech Hunter